Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19243489 | 0.85 | AR (0.69) | ARCYP2C19 | |
| SCHEMBL20113379 | 0.85 | AR (0.69) | ARCYP2C19 | |
| SCHEMBL14878986 | 0.85 | AR (0.69) | ARCYP2C19 | |
| SCHEMBL10812511 | 0.85 | AR (0.55) | AR | |
| SCHEMBL5430457 | 0.84 | AR (0.57) | ARCYP2C19 | |
| SCHEMBL2633009 | 0.80 | AR (0.50) | AR | |
| SCHEMBL16946784 | 0.80 | AR (0.52) | AR | |
| SCHEMBL22560838 | 0.79 | AR (0.68) | ARCYP2C19 | |
| SCHEMBL18814836 | 0.79 | AR (0.61) | ARCYP2C19 | |
| SCHEMBL17176192 | 0.79 | AR (0.50) | ARCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0100172-B1 | AMIDE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-08-12 | — | — | EP | claimed |
| EP-0100172-A1 | Amide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-02-08 | — | — | EP | claimed |
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| WO-2007005887-A2 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS, COMPOSITIONS AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-01-11 | — | — | WO | disclosed |
| US-5994362-A | ADMINISTERING FINASTERIDE AND CASODEX | MERCK & CO., INC. (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0514056-A2 | Use of estrogens or antiandrogens for reversal of male sexual phenotype in poultry | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| WO-1992016233-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0100172-B1 | AMIDE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-08-12 | — | — | EP | disclosed |
| US-4636505-A | ANTIANDROGENS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-01-13 | — | — | US | disclosed |
| EP-0100172-A1 | Amide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | AR 1/4885CYP2C19 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.